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MATIINGLY, B. A., J. K. ROWLETI, T. ELLISON AND K. RASE. Cocaine-induced behavioral sensitization: Effects of ha/operidol and SCH 23390 treatments. PHARMACOL BIOCHEM BEHAV 53(3) 481-486, !996.-The objective
of this study was to detennine whether the development of behavioral sensitization to cocaine could be prevented by high
doses of the dopamine receptor antagonists haloperidol and SCH 23390. In two experiments, male Wistar rats were injected
daily for 4 days with either cocaine (15 mg/kg, IP) or vehicle in combination with haloperidol (1.0 mg/kg, IP), SCH 23390
(0.5 mg/kg, SC), or vehicle, After the daily injections, the rats were tested for locomotor activity in photocell arenas. At 24 h
after the last preexposure test session, all rats were given a challenge injection of cocaine (15 mg/kg, IP) and'tested for
activity. Cocaine treatments produced a greater relative increase in locQmotor activity with repeated exposure compared to
vehicle treatments (i.e., sensitization). Moreover, the acute activating effects of cocaine over days were blocked by both
haloperidol and SCH 23390. The coadministration of haloperidol, but not SCH 23390, blocked the development of behavioral
sensitization to cocaine. That is, after the cocaine challenge injection, rats pretreated with SCH 23390 and cocaine did not
differ from rats preexposed only to cocaine, whereas rats pretreated with haloperidol and cocaine did not differ from rats
pretreated only with vehicle. Pretreatment with haloperidol or SCH 23390 without cocaine enhanced the locomotor-activating
effects of the subsequent cocaine challenge injection. These findings suggest that cocaine-induced behavioral sensitization
may develop as a result of repeated dopamine 0 1- or D2-type receptor stimulation, and that brief dopamine antagonist
treatments enhance subsequent behavioral sensitivity to cocaine.
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D 1 receptors

D2 receptors

Stimulants

THE REPEATED administration of both direct (e.g., apo·
morphine) and indirect (e.g., Cocaine, amphetamine) dopamine receptor agonists in rodents results in the development
of behavioral sensitization [e.g., (14,21,30)]. This sensitization
effect is characterized by a progressive augmentation in various drug-induced motor behaviors and appears to be mediated
by both pre- and postsynaptic mechanisms in mesolimbic and/
or nigrostriatal dopamine systems {see (11,13,28,29) for reviews].
Although most dopamine agonists that induce behavioral
sensitization result in an increased stimulation of both dopamine D.- and 0 2-receptor subtypes, recent evidence suggests
that the dopamine Di-receptor subtype plays a critical role in
the development of behavioral sensitization. The development

Dopamine agonists

Locomotor activity

of behavioral sensitization to amphetamine, for example, is
prevented by the coadministration of the selective 0 1-receptor
antagonist SCH 23390, injected either systemically or directly
into the ventral tegmental area (7,30,34). In contrast, coadministration of D 2-dopamine receptor antagonists metoclopramide, pimozide, sulpiride, or R0-22-2586, does not block
the development of behavioral sensitization to amphetamine
(7 ,34). Likewise, the development of behavioral sensitization
to the direct 0 1/Drdopamine receptor agonist apomorphine
is also prevented by the coadministration of dopamine 0 1- but
not Drreceptcir antagonists (21). Moreover, recent evidence
indicates that the development of behavioral sensitization to
the selective dopamine Drtype receptor agonists bromocryptine and quinpirole is blocked by the coadmihistration of the
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dopamine D,-type antagonist SCH 23390 (22,36). Thus, dopamine D 1-receptor stimulation appears to be necessary for the
induction of behavioral sensitization to both direct and indirect dopamine agonists.
Like amphetamine- and apomorphine-induced behavioral
· sensitization, the development of behavioral sensitization to
the locomotor-activating effects of cocaine is thought to involve the stimulation of dopamine receptors [e.g., (4,10,15,
25,32)}. Recent evidence, however, indicates that the coadministration of selective D 1-type (SCH 23390) or D2-type (sulpiride, YM-09151-2) antagonists does not prevent the development .of behavioral sensitization to cocaine (16,19). These
findings suggest the possibility that cocaine-induced behavioral sensitization, unlike amphetamine-induced sensitization,
may develop as a result of stimulation of either dopamine
receptor subtype or through some nondopaminergic mechanism.
EXPERIMENT I

Although low doses of the mixed D 1/D 2-dopamine antagonist haloperidol have been reported not to block the expression of cocaine-induced behavioral sensitization (18,35) or the
development of cocaine-induced conditioned hyperactivity
(27), 'higher doses of haloperidol have been reported to block
the development of behavioral sensitization to cocaine in a
2-day conditioning paradigm (9,35).
The purpose of Experiment 1 was to determine whether the
coadministration of a high dose of haloperidol with cocaine
would prevent the development of behavioral sensitization in
a repeated-treatment sensitization paradigm.
Method
Subjects. A total of 47 male Wistar albino rats (Harlan
Sprague-Dawley, Indianapolis, IN), weighing between 250
and 350 g, served as subjects. All rats were housed individually
in hanging wire mesh cages in a colony room with a 12 L:
12 D cycle and food and water available continuously. All
behavioral testing was conducted during the light phase of the
cycle.
Apparatus. Activity measures were taken in two BRS/LVE
cylindrical activity drums (Model 145-03; Beltsville, MD). The
floor of each drum was 60 cm in diameter and was made of
diamond-shaped wire mesh. The interior wall of each drum
was 43 cm high and painted flat black. Each drum was located
in a sound-attenuated experimental cubicle that was kept dark
during testing.
Two banks of three infrared photocells were mounted on
the outside of the drum. The six photocell beams were approximately 12 cm apart arranged in a criss-cross pattern 2.5 cm
above the floor of the drum. The photocell banks were connected to back-path eliminator diodes. Movement of the rat
through a photocell beam sent a single pulse to the counters.
Pulses spaced <0.5 s apart were recorded as a single count by
this method.
Drugs. Cocaine hydrochloride (Sigma, St. Louis, MO) was
dissolved daily into distilled H,O. Haloperidol (Sigma) was
mixed daily in a 1OJo lactic acid solution. All injections were IP
in a volume of 1.0 ml/kg. Control injections were given using
the appropriate vehicle using the same route and volume as
the corresponding drug injection. All doses were calculated
based on the salt weight of the drug.
Procedures. At the beginning of testing, the rats were randomly assigned to one of four groups (n's = 11-12/group)
comprising the two (vehicle or haloperidol) x two (vehicle or

cocaine) factorial design. On each day of the preexposure
phase of the experiment, each rat was first injected with either
vehicle or haloperidol (1.0 mg/kg) and then, 30 min later,
injected with either vehicle or cocaine (15 mg/kg). Five minutes after this second injection, each rat was placed into the
activity drum and activity was recorded for 20 min. This injection-test procedure was repeated daily for 4 days. Sensitization
testing was conducted 24 h after the last preexposure test. On
this test day, all rats were given a challenge injection of cocaine (15 mg/kg) and then tested for activity 5 min later.
Data analysis. Significant differences among the groups in
mean activity counts during the preexposure sessions were
determined with three-factor mixed analyses of variance
(ANOV A) using haloperidol and cocaine treatments as between-group factors and daily test session as a repeated measure. The cocaine challenge test data were analyzed with a
two-factor ANOVA. Significant interactions were evaluated
with additional ANOVA's followed by I-tests or NeumanKeuls post hoc tests.
Results
Preexposure days 1-4. The mean activity counts of the
four groups on the 4 preexposure days are shown in Fig. 1.
Haloperidol produced a marked decrease in locomotor activity on each test day [haloperidol effect: F(l, 43) = 185.29,
p < 0.0001]. Overall, cocaine produced an increase in activity
[cocaine effect: F(l, 43) = 33.51, p < 0.0001], but this increase was greater for rats pretreated with vehicle than for
those pretreated with haloperidol [Haloperidol x Cocaine interaction, F(l, 43) = 14.93, p < 0.0005]. Moreover, for rats
pretreated with vehicle, cocaine injections produced a greater
increase in locomotor activity compared to vehicle injections
on preexposure day 4 than on day 1 [Cocaine x Session interaction: F(3, 29) = 13.26, p < 0.05; Haloperidol x Cocaine
x Sessioninteraction:F(3, 129) = 2.84,p < 0.05].
Cocaine challenge test. The mean activity counts for the
four preexposure groups following a challenge injection of cocaine are shown in Fig. 2. The ANOVA performed on these
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FIG. 1. Mean activity counts (±SEM) per 20-min session across the
4 .preexposure days for rats injected daily with either vehicle M or 1.0
mg/kg haloperidol (H) followed by either vehicle Or 15 mg/kg cocaine
(C). •p < 0.05 compared to V-V group.
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ACUTE COCAINE CHALLENGE TEST
Cf)

1-

*

2000

+

z

6u 1600
~

>

1200

I-

~ 800

z

i':::;;:'i

09151-2 with cocaine enhanced the activating effects of a subsequent cocaine challenge injection. These investig3tors,
however, did not include an antagonist-only control group
during preexposure.
1
Although we used a relatively high dose (0.3 mg/kg) of
SCH 23390 in our previous study (19), we decided to partially
replicate this experiment using a higher dose of SCH 23390 to
determine: a) whether a high dose of SCH 23390, like haloperidol, would block the development of behavioral sensitiz3.tion
to cocaine; and b) whether a repeated high dose of SCH 23390
would significantly increase subsequent sensitivity to coc'a.ine.
Experiment 2 was therefore the same as Experiment 1, except
SCH 23390 (0.5 mg/kg), rather than haloperidol, was used.
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FIG. 2. Mean activity counts ( ± SEM) per 20-min session following a
challenge injection of cocaine (15 mg/kg) for groups of rats previously
treated daily with either vehicle or 1.0 mg/kg haloperidol and either

vehicle (VEH) or 15 mg/kg cocaine (COC) for 4 days. •p < 0.05
compared to VEHICLE-VEH group. +p

<

0.06 compared to VEHI-

CLE-YEH group.

data revealed a main effect of neither haloperidol nor cocaine
pretreatment (p's > 0.05); however, the Haloperidol x Cocaine pretreatment interaction was significant [F(l, 43) = 5.48,
p < 0.03]. Subsequent analysis of this interaction indicated that

the challenge injection of cocaine produced significantly greater
activity in rats previously treated with vehicle and cocaine for 4
days than for rats pretreated with only vehicle (p < 0.05). In
contrast, the cocaine-induced activity of rats previously treated
with haloperidol and cocaine for 4 days did not significantly
differ from that of the vehicle-vehicle-pretreated rats (p >
0.05). In other words, the coadministration of haloperidol with
cocaine for 4 days blocked the development of sensitization to
cocaine. Moreover, the challenge injection of cocaine produced
a greater activity increase in rats previously given haloperidol
and vehicle compared to rats previously given only vehicle injections (p < 0.06).
EXPERIMENT 2

,
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The results of Experiment 1 indicate that haloperidol treatments blocked the acute locomotor activating effects of cocaine over days, as well as the development of behavioral
sensitization. Although haloperidol has greater affinity for
dopamine D 2 than D 1 receptors, the fact that selective dopamine D 1- or 0 2-receptor antagonists do not block behavioral
· sensitization to cocaine (16,19) suggests that the relatively high
dose of haloperidol used in the present study may have
blocked sensitization to cocaine as a result of blocking both
D 1-and Drreceptor subtypes.
Although haloperidol treatments blocked the development
of sensitization to cocaine, repeated haloperidol treatments
alone resulted in an enhanced locomotor response to the subsequent cocaine challenge injection. In our previous study
(19), a similar but not significant enhancement in cocaine sensitivity \vas observed following repeated sulpiride or SCH
23390 treatments. Moreover, Kurihara and Uchihashi (16) reported that the coadministration of SCH 23390 or YM-

Subjects and procedure. Sixty male -Wistar albino rats
(Harlan Sprague-Dawley), weighing between 250 and 350 g,
were randomly assigned in equal numbers to one of four
groups comprising the 2 (SCH 23390 vs. vehicle) x 2 (cocaine
vs. vehicle) factorial design. SCH 23390 (Research Biochemicals) was dissolved in distilled H,O and injected SC. The apparatus and procedure was the same as in Experiment 1.
Results
Preexposure days 1-4. The mean activity counts of the
four groups across the four preexposure t'est days are shown
in Fig. 3. The 0.5-mg/kg dose of SCH ·23390 produced a
significant decrease in locomotor activitY on each test day
[SCH 23390 effect: F(I, 56) = 531.32, p < 0.0001]. Overall,
cocaine produced an increase in activity [cocaine effect: F(l,
56) = 44.30, p < 0.0001], but this increase was greater for
rats pretreated with vehicle than for those pretreated with
SCH 23390 [SCH 23390 x Cocaine interaction, F(l, 56) =
28.41, p < 0.0001]. Moreover, the cocaine-induced increase
in activity, relative to vehicle treatment, was greater for the
vehicle pretreatment group on day 4 than on day 1 [Cocaine
x Session interaction: F(3, 168) = 12.16, p < 0.0001; SCH
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FIG. 3. Mean activity counts (±SEM) per 20-min session across the
4 preexposure days for groups of rats injected daily with either vehicle (V) or 0.5 mg/kg SCH 23390 (S) followed by Cither vehicle or 15

mg/kg cocaine (C). •p < 0.05 compared to V-V gfoup.
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23390 x Cocaine x Session interaction: F(3, 168) = 7.20, p
< 0.0001].
Cocaine challenge test. The mean activity counts for the
four preexposure groups following a challenge injection of
cocaine ~re shown in Fig. 4. Although the main effect of
cocaine did not reach significance [F(I, 56) = 3.60, p <
0.06], the SCH 23390 x Cocaine interaction was significant
[F(I, 56) = 6.11,p < 0.02]. Analysis of this interaction indicated that groups of rats preexposed to cocaine and/or SCH
23390 were significantly more active following a cocaine challenge injection than rats previously treated with only vehicle
[p's < 0.05 in each case]. The activity of these three preexposed groups (i.e., vehicle-cocaine, SCH 23390-vehicle, and
SCH 23390-cocaine), however, did not differ significantly following the cocaine challenge injection [p's > 0.05 in each
case]. That is, rats preexposed to SCH 23390 and cocaine were
as active follo\ving the cocaine challenge injection as the rats
preexposed only to cocaine, and like haloperidol, preexposure
to SCH 23390 alone resulted in an increased locomotor response to cocaine.
DISCUSSION

Consistent with previous research, cocaine produced a
greater increase in locomotor activity compared to vehicle injections, with repeated treatment [e.g., (12,18,19)]. Moreover,
the acute activating effects of cocaine over days were similarly
attenuated by the coadministration of either haloperidol or
SCH 23390. This finding is also consistent with previous research [e.g., (3,7,21)], which suggests that the expression of
various dopamine agonist-induced behavioral effects requires
the concomitant stimulation of both dopamine D 1 and D 2 receptors.
Although both dopamine antagonists blocked the acute locomotor-activating effects of cocaine, only haloperidol prevented the development of behavioral sensitization. This finding is consistent with previous work which indicates that
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FIG. 4. Mean activity counts (±SEM) per 20-min session following
a challenge injection of cocaine for groups of rats previously treated
daily for 4 days with vehicle or 0.5 mg/kg SCH 23390· and either
vehicle (VEH) or 15 mg/kg cocaine (COC). •p < 0.05 compared to
VEHICLE-VEH group.

coadministration of a relatively high dose of haloperidol (0.5
mg/kg) blocks the development of sensitization to a single
high dose (40 mg/kg) of cocaine (35). Similarly, haloperidol
also blocks the development of sensitization to repeated apomorphine treatments (20). As· noted previously, the coadministration of more selective dopamine Drtype antagonists does
not prevent the development of sensitization to cocaine (16,
19), amphetamine (7,30,34), or apomorphine (21). Likewise,
selective dopamine D 1-type antagonists are ineffective in
blocking cocaine-induced behavioral sensitization (Experiment 2) (16,19). Taken together, these findings suggest that
the prevention of cocaine-induced behavioral sensitization
may require the blockade of both dopamine D,- and D2-type
receptors.
It should be noted, however, that the neurochemical effects
of cocaine and haloperidol are not limited to dopamine systems. Cocaine, for example, blocks neuronal reuptake of serotonin and norepinepbrine as well as dopamine (8). Moreover,
the acute locomotor-activating effects of cocaine are blocked
by adrenergic, serotonergic, and a-receptor antagonists (2,31,
37), and repeated cocaine treatments produce alterations in
other neurochemical systems besides dopamine (6,17,33).
Likewise, in addition to dopamine receptors, haloperidol has
been reported to bind to both serotonin and sigma sites
(23,26). Thus, it is possible that the ability of high doses of
haloperidol to block the development of cocaine-induced behavioral sensitization may be related to its nondopaminergic
effects or to some combination of dopaminergic and nondopaminergic effects.
Also, it might be argued that the effectiveness of haloperidol in blocking the development of behavioral sensitization to
cocaine, compared to other dopamine antagonists, may be
related to its rather long ·half-life. In rats, the brain tissue
half-life of haloperidol has been reported to be approximately
5 h (5). Because the cocaine challenge test was conducted only
24 h following the last the haloperidol treatment, a small
amount of haloperidol may have been present, thereby reducing the locomotor-activating effects of cocaine. If this latter
explanation were· correct, however, the cocaine-induced activity increase observed in rats previously treated with haloperidol and vehicle for 4 days would also have been significantly
reduced. As noted previously, the cocaine-induced activity of
these haloperidol-treated rats did not differ significantly from
that of rats previously treated with only cocaine (cf., Fig. 2).
Thus, drug accumulation would not appear to account for the
effectiveness of haloperidol in preventing the development of
behavioral sensitization to cocaine.
Another intriguing, yet complicating, finding of the present study is that brief treatments (i.e., 4 days) with relatively
high doses of either haloperidol or SCH 23390 enhanced the
locomotor-activating effects of a subsequent cocaine challenge
injection. As noted earlier, we observed a similar tendency
after seven daily injections of sulpiride (100 mg/kg) or a lower
dose of SCH 23390 (0.30 mg/kg) in a previous study with rats
(19); and Kurihara and Uchihashi (16) reported that coadministration of SCH 23390 or YM-09151-2 with cocaine increases
subsequent sensitivity to cocaine in mice. Consistent with
these antagonist-induced changes in cocaine sensitivity, it has
recently been reported that four daily treatments with the selective dopamine D,-type agonist A-77636 decreases subsequent sensitivity to the locomotor-activating effects of cocaine
(1). Moreover, repeated treatment (5 days) with the mixed
dopamine antagonist cis-(Z)-flupentixol has recently been reported to increase subsequent sensitivity to cocaine in a selfadministration paradigm (24). Thus, brief antagonist treat-
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ments appear to enhance sensitivity to both the locomotor and
rewarding effects of cocaine.
Although this antagonist-induced increase in cocaine sensitivity is interesting, it complicates the interpretation of the
sensitization results. For example, in Experiment 2, rats preexposed to SCH 23390 and cocaine did not differ in activity
from those pretreated only with cocaine on the cocaine challenge test. This suggests that SCH 23390 did not block the
development of sensitization to cocaine. However. the SCH
23390-cocaine-pretreated rats also did not differ in activity
from rats previously treated with only SCH 23390 on this
cocaine challenge test. Because cocaine pretreatment did not
add to the effect of SCH 23390 pretreatment, it might be
argued that SCH 23390 did block cocaine-induced sensitization. Thus, it is possible that any attenuation of sensitization
to cocaine resulting from the coadministration of selective
antagonists might be masked by the antagonist-induced increase in cocaine sensitivity. Clearly, additional information
concerning the mechanisms mediating this brief antagonistinduced increase in cocaine sensitivity is needed before an
unambiguous interpretation is possible. Although haloperidol
pretreatments also increased subsequent sensitivity to cocaine,
rats pretreated with haloperidol and cocaine did not differ
after the cocaine challenge injection from rats pretreated with
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only vehicle for 4 days. Thus, haloperidol clearly blocked the
development of sensitization.
In conclusion, the present results indicate that brief pretreatments with either haloperidol or SCH 23390 increase subsequent sensitivity to cocaine. Further, the results indicate that
high doses of haloperidol, but not SCH 23390, block the development of behavioral sensitization to cocaine. These findings, together with previous research, sukgest that cocalneinduced behavioral sensitization may be' mediated by the
repeated stimulation of either dopamine; receptor subtype
alone. Moreover, because sensitization to!amphetamine and
apomorphine, but not cocaine, is prevented by selective dopamine D1-type antagonists [e.g., (7,19,21,34)], these results suggest that the development of sensitization to these three dopamine agonists may be mediated by different neurochemical
mechanisms.
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